Mithra Announces Positive Top-Line Results from Donesta® Phase 3 Studies in Menopausal Women

Liege, Belgium, 14 January 2022 – 07:30 CET – Mithra (Euronext Brussels: MITRA), a company
dedicated to Women’s Health, today announces positive efficacy top-line results from Donesta® Phase
3 pivotal “E4 Comfort” clinical trials for the treatment of Vasomotor Symptoms (VMS) in postmenopausal women. Donesta® is Mithra’s next generation orally-administrated estetrol (E4)-based
hormone therapy product candidate.